Medytox Venture Investment
VC Fund
Seoul, South Korea
Medytox Venture Investment is a TIPS operator that provides opportunities and supports growth in the healthcare sector.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries Medytox Venture Investment invests in
Stages Medytox Venture Investment invests in
Countries Medytox Venture Investment invests in
Round sizes
Round size
- Seed
- $3M–$3.4M
- Series A
- $3.4M–$15M
- Series B
- $4k–$44M
Investment Focus
Industry
- Biotechnology 15 (65%)
- Pharmaceutical 11 (48%)
- Medical 6 (26%)
- Health Care 6 (26%)
- Life Science 4 (17%)
Stage
- Series A 9 (39%)
- Series B 5 (22%)
- Seed 4 (17%)
- Series C 4 (17%)
- Pre-Seed 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nex Eye
|
Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $44.2M / Series B / Aug 13, 2025 | |
Dime Bio
|
Dime Bio is a drug development company for novel dementia treatments. | $8.2M / Series A / Mar 26, 2025 | |
Inventera Pharmaceuticals
|
Inventera Pharmaceutical is a biotechnology company that specializes in the development of imaging diagnostic contrast agents. | $13.4M / Series C / Oct 30, 2024 | |
AIGEN Sciences
|
AIGEN Sciences is an AI drug discovery platform that provides drug research and development services. | $8.8M / Series A / Oct 16, 2024 | |
Avelos Therapeutics
|
Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. | $12.4M / Series B / May 02, 2024 | |
GPCR Therapeutics
|
GPCR Therapeutics is a clinical-stage international biopharmaceutical firm that develops therapeutics based on proprietary GPCR data. The company was founded in 2013 and is headquartered in Seoul, South Korea. The company’s proprietary data driven approach has identified over 1000 GPCR pairs upon which drug screening campaigns can be pursued.Identification of the best GPCR pair to target for specific disease indications and patient subpopulations creates a personalized approach to combination therapy. By targeting the unique pharmacology of GPCR pairs, we aim to develop life changing treatments for cancer and other diseases. | $3.2M / Series C / Nov 29, 2023 | |
Zymedi
|
Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases. | $12.1M / Series A / May 30, 2023 | |
Ubix Therapeutics
|
Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $9.2M / Series C / Mar 28, 2023 | |
AinB
|
AinB is a biotechnology startup focused on applying artificial intelligence (AI) to the discovery and development of novel biologic drugs, particularly antibody therapeutics. By combining scientific expertise in antibody therapeutics with advanced AI capabilities, the company aims to develop innovative treatments more efficiently and strengthenKorea’s competitiveness in the global biopharmaceutical industry. | Seed / Mar 15, 2023 | |
|
Nex Eye
|
Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $15.4M / Series A / Oct 07, 2022 | |
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Medytox Venture Investment invest in?
Medytox Venture Investment invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Medytox Venture Investment's check size?
Medytox Venture Investment typically joins rounds of $3M–$3.4M at Seed, $3.4M–$15M at Series A and $4k–$44M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Medytox Venture Investment participates in.
When did Medytox Venture Investment last invest?
The most recent investment recorded for Medytox Venture Investment closed in Aug 2025. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
